Frequency of injecting among people who inject drugs: A systematic review and meta-analysis.

Harm reduction Injecting behaviour Injecting drug use Needle and syringe programmes Needle–syringe distribution coverage People who inject drugs Population size

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
02 2020
Historique:
received: 17 05 2019
revised: 29 10 2019
accepted: 03 12 2019
pubmed: 22 12 2019
medline: 29 7 2021
entrez: 22 12 2019
Statut: ppublish

Résumé

People who inject drugs (PWID) do so at varying frequencies. More frequent injecting is associated with skin and soft tissue infection, blood borne viruses, and overdose. The aims of this review are to estimate the prevalence of injecting frequency among PWID and compare these estimates to current needle-syringe distribution coverage estimates, and identify socio-demographic and risk characteristics, and harms associated with daily or more injecting. We conducted a systematic review of the peer-reviewed and grey literature from 2008 to 2018 and extracted needle-syringe distribution coverage data from a recent systematic review. We generated country-, region-, and global-level estimates of daily or more injecting. We also ran meta-regression analyses to determine associations between daily or more injecting and socio-demographic characteristics, injecting risk behaviour, non-fatal overdose, injection site skin infection, and blood borne virus prevalence. Our search resulted in 61,077 sources, from which 198 studies were eligible for inclusion in this review. There were 74 countries with estimates for injecting frequency. Globally, we estimated that 68.1% (95%CI 64.5-71.6%) of PWID, equating to approximately 10.5 (95% UI 6.8-15.0) million people, inject daily or more frequently. There was a higher percentage of participants reporting daily or more injecting among samples with shorter injecting careers, more male participants and higher reporting of opioids as their main drug injected. Daily or more injecting was also associated with samples reporting a higher prevalence of HIV and hepatitis C antibody (anti-HCV), non-fatal overdose, and receptive needle sharing in the previous month. WHO recently recommended a needle-syringe distribution target of 300 needles per PWID per year which is unlikely to be sufficient for the majority of PWID injecting daily or more who are out of drug treatment. The Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, University of New South Wales.

Sections du résumé

BACKGROUND
People who inject drugs (PWID) do so at varying frequencies. More frequent injecting is associated with skin and soft tissue infection, blood borne viruses, and overdose. The aims of this review are to estimate the prevalence of injecting frequency among PWID and compare these estimates to current needle-syringe distribution coverage estimates, and identify socio-demographic and risk characteristics, and harms associated with daily or more injecting.
METHODS
We conducted a systematic review of the peer-reviewed and grey literature from 2008 to 2018 and extracted needle-syringe distribution coverage data from a recent systematic review. We generated country-, region-, and global-level estimates of daily or more injecting. We also ran meta-regression analyses to determine associations between daily or more injecting and socio-demographic characteristics, injecting risk behaviour, non-fatal overdose, injection site skin infection, and blood borne virus prevalence.
RESULTS
Our search resulted in 61,077 sources, from which 198 studies were eligible for inclusion in this review. There were 74 countries with estimates for injecting frequency. Globally, we estimated that 68.1% (95%CI 64.5-71.6%) of PWID, equating to approximately 10.5 (95% UI 6.8-15.0) million people, inject daily or more frequently. There was a higher percentage of participants reporting daily or more injecting among samples with shorter injecting careers, more male participants and higher reporting of opioids as their main drug injected. Daily or more injecting was also associated with samples reporting a higher prevalence of HIV and hepatitis C antibody (anti-HCV), non-fatal overdose, and receptive needle sharing in the previous month.
IMPLICATIONS
WHO recently recommended a needle-syringe distribution target of 300 needles per PWID per year which is unlikely to be sufficient for the majority of PWID injecting daily or more who are out of drug treatment.
FUNDING
The Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, University of New South Wales.

Identifiants

pubmed: 31864107
pii: S0955-3959(19)30333-0
doi: 10.1016/j.drugpo.2019.102619
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102619

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA044170
Pays : United States
Organisme : Department of Health
ID : RP-DG-0610-10055
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0616-20008
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Samantha Colledge (S)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, 2052 New South Wales, Australia. Electronic address: s.colledge@student.unsw.edu.au.

Janni Leung (J)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, 2052 New South Wales, Australia; School of Pyschology, The University of Queensland, Brisbane, 4072, Queensland, Australia.

Sarah Larney (S)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, 2052 New South Wales, Australia.

Amy Peacock (A)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, 2052 New South Wales, Australia.

Jason Grebely (J)

The Kirby Institute, UNSW Sydney, Sydney, 2052, New South Wales, Australia.

Matthew Hickman (M)

Population Health Sciences, University of Bristol, BS8 1QU, Bristol, United Kingdom; National Institute of Health Research, Health Protection Research Unit in Evaluation of Interventions, Bristol Medical School, BS8 1QU, Bristol, United Kingdom.

Evan Cunningham (E)

The Kirby Institute, UNSW Sydney, Sydney, 2052, New South Wales, Australia.

Adam Trickey (A)

Population Health Sciences, University of Bristol, BS8 1QU, Bristol, United Kingdom; National Institute of Health Research, Health Protection Research Unit in Evaluation of Interventions, Bristol Medical School, BS8 1QU, Bristol, United Kingdom.

Jack Stone (J)

Population Health Sciences, University of Bristol, BS8 1QU, Bristol, United Kingdom.

Peter Vickerman (P)

Population Health Sciences, University of Bristol, BS8 1QU, Bristol, United Kingdom; National Institute of Health Research, Health Protection Research Unit in Evaluation of Interventions, Bristol Medical School, BS8 1QU, Bristol, United Kingdom.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, 2052 New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH